Group B Streptococcal Conjugate Vaccines

Overview

Journal Arch Dis Child

Specialty Pediatrics

Date 2003 Apr 30

PMID 12716700

Citations 40

Authors

C J Baker

M S Edwards

Affiliations

Soon will be listed here.

Abstract

Linkage of bacterial capsular polysaccharides to proteins to create conjugate vaccines has had a dramatic impact on the health of children. Although unconjugated polysaccharides are poorly immunogenic in infants and some older children and adults, their covalent coupling with proteins stimulates T cell dependent antigenic recognition that profoundly enhances immunogenicity. In the decade since the introduction and widespread use of Haemophilus influenzae type b polysaccharide conjugate vaccines in the United States, invasive H influenzae infections have become a rarity in childhood. Similarly, the conjugation of polysaccharides of Streptococcus pneumoniae to a derivative of diphtheria toxoid and the addition of pneumococcal conjugate vaccine to infant immunisation schedules carries with it promise for a similar decline in the incidence of invasive pneumococcal disease in paediatric patients.

Citing Articles

Effect of Side-Chain Functional Groups in the Immunogenicity of Bacterial Surface Glycans.

Tian G, Qin C, Hu J, Zou X, Yin J Molecules. 2023; 28(20).

PMID: 37894591 PMC: 10609480. DOI: 10.3390/molecules28207112.

Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles.

Carboni F, Cozzi R, Romagnoli G, Tuscano G, Balocchi C, Buffi G NPJ Vaccines. 2023; 8(1):152.

PMID: 37803013 PMC: 10558462. DOI: 10.1038/s41541-023-00744-5.

Immune responses against group B monovalent and pentavalent capsular polysaccharide tetanus toxoid conjugate vaccines in Balb/c mice.

Dhar N, Mohamed E, Kirstein F, Williams M, Dorasamy S, van Zyl P iScience. 2023; 26(8):107380.

PMID: 37575182 PMC: 10415928. DOI: 10.1016/j.isci.2023.107380.

Group B Streptococcus: Virulence Factors and Pathogenic Mechanism.

Liu Y, Liu J Microorganisms. 2022; 10(12).

PMID: 36557736 PMC: 9784991. DOI: 10.3390/microorganisms10122483.

Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection.

Chiarot E, Naimo E, Corrado A, Giannetti P, Margarit Y Ros I, Bensi G Sci Rep. 2021; 11(1):21384.

PMID: 34725414 PMC: 8560876. DOI: 10.1038/s41598-021-00941-z.

References

Schrag S, Zywicki S, Farley M, Reingold A, Harrison L, Lefkowitz L . Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000; 342(1):15-20. DOI: 10.1056/NEJM200001063420103. View

Baker C, Paoletti L, Wessels M, Guttormsen H, Rench M, Hickman M . Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis. 1998; 179(1):142-50. DOI: 10.1086/314574. View

Baker C, Paoletti L, Rench M, Guttormsen H, Carey V, Hickman M . Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis. 2000; 182(4):1129-38. DOI: 10.1086/315839. View

Henning K, Hall E, Dwyer D, Billmann L, Schuchat A, Johnson J . Invasive group B streptococcal disease in Maryland nursing home residents. J Infect Dis. 2001; 183(7):1138-42. DOI: 10.1086/319278. View

Farley M . Group B streptococcal disease in nonpregnant adults. Clin Infect Dis. 2001; 33(4):556-61. DOI: 10.1086/322696. View

Schuchat A . Group B streptococcal disease: from trials and tribulations to triumph and trepidation. Clin Infect Dis. 2001; 33(6):751-6. DOI: 10.1086/322697. View

Lin F, Philips 3rd J, Azimi P, Weisman L, Clark P, Rhoads G . Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis. 2001; 184(8):1022-8. DOI: 10.1086/323350. View

Paradiso P . Maternal immunization: the influence of liability issues on vaccine development. Vaccine. 2001; 20 Suppl 1:S73-4. DOI: 10.1016/s0264-410x(01)00302-4. View

Paoletti L, Rench M, Kasper D, Molrine D, Ambrosino D, Baker C . Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect Immun. 2001; 69(11):6696-701. PMC: 100045. DOI: 10.1128/IAI.69.11.6696-6701.2001. View

10.

Murdoch D, Reller L . Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective. Antimicrob Agents Chemother. 2001; 45(12):3623-4. PMC: 90883. DOI: 10.1128/AAC.45.12.3623-3624.2001. View

11.

Obaro S, Adegbola R . The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol. 2002; 51(2):98-104. DOI: 10.1099/0022-1317-51-2-98. View

12.

Baker C, Kasper D . Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976; 294(14):753-6. DOI: 10.1056/NEJM197604012941404. View

13.

Baker C, Kasper D . Group B streptococcal vaccines. Rev Infect Dis. 1985; 7(4):458-67. DOI: 10.1093/clinids/7.4.458. View

14.

Baker C, Rench M, Edwards M, Carpenter R, Hays B, Kasper D . Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med. 1988; 319(18):1180-5. DOI: 10.1056/NEJM198811033191802. View

15.

Wessels M, Paoletti L, Kasper D, Difabio J, Michon F, Holme K . Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest. 1990; 86(5):1428-33. PMC: 296886. DOI: 10.1172/JCI114858. View

16.

Whitman C, Belgharbi L, Gasse F, Torel C, Mattei V, Zoffmann H . Progress towards the global elimination of neonatal tetanus. World Health Stat Q. 1992; 45(2-3):248-56. View

17.

Kasper D, Paoletti L, Wessels M, Guttormsen H, Carey V, Jennings H . Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest. 1996; 98(10):2308-14. PMC: 507681. DOI: 10.1172/JCI119042. View

18.

Munoz P, Llancaqueo A, Rodriguez-Creixems M, Pelaez T, Martin L, Bouza E . Group B streptococcus bacteremia in nonpregnant adults. Arch Intern Med. 1997; 157(2):213-6. DOI: 10.1001/archinte.1997.00440230087011. View

19.

Harrison L, Elliott J, Dwyer D, Libonati J, Ferrieri P, Billmann L . Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis. 1998; 177(4):998-1002. DOI: 10.1086/515260. View

20.

Fernandez M, Hickman M, Baker C . Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother. 1998; 42(6):1517-9. PMC: 105636. DOI: 10.1128/AAC.42.6.1517. View